PharmaFocus Today – Page 7 – media

Behind the sales difference between China and the United States

When it comes to innovative anesthetic sedative drugs launched in recent years, remimazolam is undoubtedly a variety worthy of attention. Remimazolam was designed and synthesized by GSK in 1999. After changing hands many times, it was approved for marketing in China, the United States, Europe and other countries almost simultaneously around 2020. However, the author found that the sales volume of the drug after its launch in different countries varies greatly. In 2023, the sales volume of remimazolam in China was about 40 million US dollars, while that in the United States was only 800,000 US dollars, which is about 2% of the Chinese market. Why is there such a difference? It is reported that remimazolam, a “new star” in the field of anesthesia, is an ultra-short-acting GABAA receptor agonist that combines the characteristics of midazolam and remifentanil, two anesthetics. Like midazolam, it acts on GABA receptors, but like remifentanil, ...
- Source: drugdu
- 47
- December 11, 2024
Challenging the “Cancer King”

Revolution Medicines recently announced that its pan-RAS inhibitor RMC-6236 has shown significant anti-tumor effects and good safety in the treatment of patients with pancreatic ductal adenocarcinoma (PDAC) who have undergone other treatments. The study results show that RMC-6236, as a single drug for second-line treatment, can improve the median progression-free survival (PFS) and overall survival (OS) of PDAC patients carrying RAS mutations. Among them, the overall survival of patients at 6 months The rate data are impressive: 100% for patients with KRAS G12X mutations and 97% for patients with any RAS mutation. Pan-KRAS inhibitors have been making rapid progress, challenging the “king of cancers” pancreatic cancer. The toughest target? Pancreatic cancer is a malignant tumor with a high mortality rate, and RAS gene mutations have an important impact on the occurrence and development of pancreatic cancer. Data show that about 85% to 95% of pancreatic cancer patients have RAS mutations, ...
- Source: drugdu
- 52
- December 11, 2024
580 million! Peripheral vascular innovation equipment company completes Series B financing

According to the Medicine Intelligence Data Investment Pattern Database, VFLO Medical, a peripheral vascular innovation medical device company, recently announced the completion of a Series B financing with a total amount of $80 million (approximately RMB 581 million). The financing was jointly participated by well-known investment institutions such as Tonghe Yucheng and its US dollar fund 120 Capital, a large family office, Hefei Production Investment, Hefei High tech Investment, and USTC Silicon Valley. It is reported that the funds raised in this round will be used to support the clinical and promotion of innovative pipelines in the peripheral intervention field developed by Jitong Medical through multiple collaborations and self research. The aim is to meet the huge clinical demand in China’s peripheral vascular field and bring more cutting-edge solutions for the treatment of peripheral vascular diseases. Founded in 2021, Yitong Medical is jointly incubated by Tonghe Yucheng and 120 Capital. ...
- Source: drugdu
- 51
- December 11, 2024
GE Healthcare Swallows Japanese Nuclear Drug Giant

Recently, GE Healthcare announced that it will acquire the remaining 50% stake in Nihon Medi Physics (NMP) from Sumitomo Chemical, achieving full takeover of NMP. The transaction is expected to be completed in early 2025, subject to regulatory approval. According to Sumitomo Chemical’s announcement, this transaction is expected to bring approximately 30 billion yen (approximately 1.455 billion yuan) in revenue growth. Master of Nuclear Medicine Acquisition NMP was founded in 1973, headquartered in Tokyo, Japan, initially as a joint venture between British life sciences company Amersham and Sumitomo Chemical. Since its establishment, NMP has been committed to providing a range of radiopharmaceuticals as diagnostic agents, enabling doctors to observe the function of internal organs in the human body through imaging technology and detect the presence and progression of diseases. Nowadays, NMP has strong capabilities in molecular imaging programs such as single photon emission computed tomography (SPECT) and positron emission tomography ...
- Source: drugdu
- 48
- December 11, 2024
Building a diversified business ecosystem, Tai’enkang’s growth ceiling is expected to be opened

Source: Daily Economic News Tai’enkang, which is accelerating its layout in the life science and health industry, has recently achieved continuous good news. Recently, the company’s CKBA ointment Phase II clinical trial completed the enrollment of all subjects. If approved for listing in the future, it is expected to become a heavyweight product of the company and create new growth points for the company. As the company focuses on innovative drugs that can break monopolies, truly address unmet clinical needs, and fill clinical gaps, building a diverse and collaborative business ecosystem will inject momentum into the long-term development of the enterprise. CKBA is making rapid progress In just one year, Taienkang has made new progress in the research and development of vitiligo drugs. Recently, Taien Kang announced that its subsidiary, Jiangsu Bochuangyuan Biomedical Technology Co., Ltd., has completed the enrollment of all subjects for the Class 1 innovative drug CKBA ...
- Source: drugdu
- 54
- December 10, 2024
Wanxiang WIL Meta ® 3D C-arm machine “and Tianzhihang” Tianji ® Orthopedic surgical robots are interconnected and interconnected

Recently, Suzhou Yimu Wanxiang Technology Co., Ltd. (hereinafter referred to as “Wanxiang Technology”) joined hands with Beijing Tianzhihang Medical Technology Co., Ltd. (hereinafter referred to as “Tianzhihang”) to discuss their core product – “WIL Meta” ® Yuanxiang Series 3D C-arm Machine “and” Tianji ® In depth communication and exploration of deep cooperation on orthopedic surgical robots. Wanxiang Technology and Tianzhihang are respectively deeply rooted in the fields of surgical imaging and orthopedic surgical robots, each with leading technological advantages and rich clinical experience. Through this collaboration, both parties will deeply combine their respective technological advantages and jointly explore new paths for smart healthcare, providing more accurate, efficient, and safe solutions for clinical practice. As the flagship product of Wanxiang Technology, WIL Meta ® The Yuanxiang series 3D C-arm machine, with its highly integrated features, ultimate compactness and lightness, fast scanning, large imaging, customized 3D, AI empowerment and other professional advantages, ...
- Source: drugdu
- 54
- December 10, 2024
Leading blood equipment company, selling off mainline business

On December 3, 2024, Haemonetics announced that the company had agreed to sell its whole blood assets (whole blood collection, processing, and filtration solution portfolio) to GVS S.p.A for $67.1 million. GVS, a manufacturer providing filtering solutions for healthcare and life sciences, has agreed to pay $44.6 million upfront. The transaction also includes up to $22.5 million in contingent income payments over the next four years. 01. Sell off whole blood business and focus on plasma field According to the terms of this agreement, GVS will acquire all proprietary whole blood collection, processing, and filtration solutions from Haemonetics. At the same time, GVS will also take over Haemonetics’ manufacturing plant in Covina, California, which produces some of the aforementioned products. In addition, GVS also acquired the relevant equipment and assets of Haemonetics’ Boston headquarters located in Tijuana, Mexico. Previously, Haemonetics had announced plans to terminate its online blood collection business ...
- Source: drugdu
- 46
- December 10, 2024
Hengrui Medicine’s IL-17A monoclonal antibody price cut by 57%

Only three months after its launch, Hengrui Medicine’s IL-17A monoclonal antibody Funaqizumab has reduced its price. On December 2, the Jiangsu Provincial Public Resources Trading Center issued an announcement that the online prices of some drugs were adjusted, among which the price of Funaqizumab was reduced from 1,986 yuan per vial to 860 yuan, a reduction of more than 56%. As Funaqizumab has only been on the market for three months, Hengrui Medicine has chosen to reduce its price, which is rare. Of course, it is understandable that Funaqizumab was approved in August and failed to catch up with this year’s medical insurance negotiations, and faced considerable pressure. In China, Sicuzumab is one of the most innovative drugs that actively embraces medical insurance negotiations. Its successive price cuts have broken the limitations of the autoimmune drug market. In May this year, Novartis said that Secukinumab has covered more than 500,000 ...
- Source: drugdu
- 53
- December 10, 2024
Everest’s “hidden gold mine” emerges

The high value of EVER001 is related to the market it is in. The potential treatment population is huge, the clinical burden is heavy, and effective treatment is scarce, which determines that the field of kidney disease is a super blue ocean market. Take the primary membranous nephropathy market as an example. As the most common pathological type of adult kidney disease, there are nearly 2 million cases of primary membranous nephropathy in China, and the total number of patients in the United States, Europe, Japan and other countries exceeds 200,000. Primary membranous nephropathy can cause renal failure. The “Future landscape for the management of membranous nephropathy” published in the Journal of Clinical Nephrology in August 2023 showed that if left untreated, 14% of patients with persistent nephrotic syndrome may develop renal failure at 5 years, 35% at 10 years, and 41% at 15 years. Unfortunately, no specific drug has ...
- Source: drugdu
- 53
- December 10, 2024
To solve the problem of paying for sky-high-priced drugs, the US health insurance has set an example

“Sky-high” has almost become an exclusive adjective for gene therapy, and there is no most expensive, only more expensive. On August 17, 2022, the US FDA announced the approval of Zynteglo, a gene therapy developed by Bluebird, for the treatment of patients with β-thalassemia. Zynteglo is priced at $2.8 million, making it the most expensive therapy in the world at the time. On September 16 of that year, Skysona, another gene therapy of Bluebird, was approved by the FDA for the treatment of the rare neurological disease “brain adrenoleukodystrophy”, priced at $3 million. Subsequently, the FDA approved the listing of Hemgenix, a gene therapy jointly developed by CSL and UniQure, for the treatment of hemophilia B. The price of one dose is $3.5 million, once again breaking the record of the world’s most expensive drug. Despite the potential to solve the problem once and for all, the high price has ...
- Source: drugdu
- 51
- December 10, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.